Home › Immune System and Disorders › Connecticut › New Haven
Immune System and Disorders clinical trials in New Haven, CT
3 studies for Immune System and Disorders are looking for participants at sites in and around New Haven (within about 30 miles). Open a study to see who can join and how to contact the study team.
Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
RecruitingObservational study
- Veterans Affairs Connecticut Healthcare System-West Haven Campus, West Haven · 3 mi away
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
RecruitingPhase 1/2
- Yale School of Medicine, New Haven
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
RecruitingPhase 1/2
- Yale University, New Haven
About Immune System and Disorders
Your immune system is made up of cells, tissues, and organs that fight infections and diseases. Learn how it works, and about diseases of the immune system.
More about Immune System and Disorders on MedlinePlus
Immune System and Disorders trials in other cities
- Washington, DC13 studies
- New York City, NY12 studies
- Boston, MA10 studies
- Philadelphia, PA10 studies
- Atlanta, GA9 studies
- Houston, TX9 studies
- Portland, OR9 studies
- Cleveland, OH8 studies
- Los Angeles, CA8 studies
- Chicago, IL8 studies
- Seattle, WA6 studies
- Cedar Rapids, IA6 studies
Other studies in New Haven
- Non-Small Cell Lung Cancer41 studies
- Breast Cancer37 studies
- Cancer (all types)34 studies
- Metastatic Cancer23 studies
- Lung Cancer23 studies
- Head and Neck Squamous Cell Carcinoma22 studies
- Colorectal Cancer21 studies
- Prostate Cancer21 studies
- Ovarian Cancer21 studies
- Acute Myeloid Leukemia19 studies
- Alcohol Use Disorder (AUD)17 studies
- Opioid Overdose17 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.